retatrutide phase 2 trial new england journal of medicine Once-Monthly Maridebart Cafraglutide for the Treatment Obesity — A Retatrutide Shows Promising Weight Loss
Description
Finucane OM, Sugrue J, Rubio-Araiz A, Guillot-Sestier MV, Lynch MA
The estimated mean weight loss was 7.03 kg in the placebo group, 11.19 kg in the exercise group, 13.74 kg in the liraglutide group, and 16.88 kg in the combination group
It is a highly effective option for those seeking maximum medical support
[DOI] [PubMed] [Google Scholar] 67.Deshmane S.L., Kremlev S., Amini S., Sawaya B.E
